Analyst Downgrades: American Water Works Company Inc, Boeing Co, and Valeant Pharmaceuticals Intl Inc

Analysts downwardly revised their ratings and price targets on American Water Works Company Inc (AWK), Boeing Co (BA), and Valeant Pharmaceuticals Intl Inc (VRX)

Mar 2, 2016 at 9:47 AM
facebook twitter linkedin


Analysts are weighing in on utilities firm American Water Works Company Inc (NYSE:AWK), aerospace issue Boeing Co (NYSE:BA), and drugmaker Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Here's a quick roundup of today's bearish brokerage notes on AWK, BA, and VRX.

  • Apparently, Baird isn't impressed with last night's news that AWK will replace CONSOL Energy Inc. (NYSE:CNX) on the S&P 500 Index (SPX). Specifically, the brokerage hit the water stock with a downgrade to "neutral" from "outperform." Nonetheless, American Water Works Company Inc is 4.1% higher out of the gate at $67.98, a chip-shot from last week's record high of $68.49. While Baird isn't a fan of the shares, plenty of other analysts are. Two-thirds of covering brokerage firms rate AWK a "buy" or better, with not a single "sell" opinion on the books.
  • In what's becoming a daily routine, VRX has received more negative analyst attention. This time, Canaccord Genuity downgraded its rating to "hold" from "buy," and cut its price target $50 to $75. In other news, Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) said it's received an additional milestone payment from Valeant Pharmaceuticals Intl Inc for its development of an experiment eye inflammation drug. Out of the gate, the stock is 4% higher at $68.05, but has already lost 33% in 2016. Additional downgrades remain a possibility, as nine analysts maintain "strong buy" endorsements on VRX, compared to six "holds" and just one "strong sell."
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners